Eli Lilly and Co said on Tuesday its experimental treatment for an inflammatory bowel disease succeeded in a late-stage trial.
The drug, mirikizumab, met the main goal of showing reduced bowel urgency in moderate to severe ulcerative colitis.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
